ASCO 2025: AI Takes the Stage, Trials Reshape Standards, and China Steps Forward

In this extended wrap-up from ASCO 2025, Mike breaks down four defining themes from the meeting: AI’s leap from buzzword to bedside, NIH funding threats that could shake innovation, China’s rising role in global oncology R&D, and five paradigm-shifting clinical trials with the potential to reshape patient care. Featuring insights from ASCO leadership, Google, and frontline HCPs from the ZoomRx panel, this is your all-in-one debrief on the most important takeaways from the year’s biggest oncology conference.